Page last updated: 2024-11-04

sb 202190 and Carcinoma, Medullary

sb 202190 has been researched along with Carcinoma, Medullary in 1 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, Z1
Falola, J1
Zhu, X1
Gu, Y1
Kim, LT1
Sarosi, GA1
Anthony, T1
Nwariaku, FE1

Other Studies

1 other study available for sb 202190 and Carcinoma, Medullary

ArticleYear
Antiproliferative effects of Src inhibition on medullary thyroid cancer.
    The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:7

    Topics: Apoptosis; Carcinoma, Medullary; Cell Division; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Enzym

2004